Improve Myeloma Induction Therapy with Nutrition

Can Your Gut Microbiome Improve Multiple Myeloma Induction Therapy?

Can Your Gut Microbiome Improve Multiple Myeloma Induction Therapy? Research suggests the gut microbiome may influence immune function, treatment response, and recovery during multiple myeloma induction therapy. Learn what the evidence says—and what you can do today.

According to research, more than 90% of newly diagnosed multiple myeloma (MM) patients “respond” to their induction therapy. This response can be complete, partial, or none. The newly diagnosed MM patient’s response to their induction therapy can make a measurable difference to that patient’s overall survival.

Consider non-toxic therapies to enhance your response to your induction therapy. Therapies that may also reduce your side effects.

Scroll down the page and post a question or a comment if there’s anything you’d like to know about breast cancer.

Good luck,

David Emerson

Your First Myeloma Treatment: Understanding the Goals of Induction Therapy

Can Your Gut Microbiome Improve Multiple Myeloma Induction Therapy?

Short answer: Maybe—but not by itself.

Growing research suggests that your gut microbiome—the trillions of bacteria living in your digestive tract—may influence how well your immune system responds to multiple myeloma treatment. While researchers cannot yet recommend probiotics or special diets as a standard part of induction therapy, maintaining a healthy gut microbiome may improve immune function, reduce complications, and possibly enhance treatment response.

As a long-term multiple myeloma survivor, I’ve learned that successful treatment isn’t just about killing cancer cells. It’s also about helping your body recover, reducing treatment toxicity, and supporting the immune system throughout therapy.

What Is Induction Therapy?

Induction therapy is the first phase of treatment after a multiple myeloma diagnosis.

Its goals include:

Destroying as many myeloma cells as possible
Achieving a deep remission
Preparing eligible patients for autologous stem cell transplantation (ASCT)
Improving long-term survival

Modern induction therapy often includes combinations such as:

Proteasome inhibitors (bortezomib)
Immunomodulatory drugs (lenalidomide)
Corticosteroids (dexamethasone)
Monoclonal antibodies (daratumumab)

These therapies are remarkably effective—but they also affect the immune system and may indirectly alter the gut microbiome through chemotherapy, steroids, antibiotics, and changes in diet.

Why Does the Gut Microbiome Matter?

The gut microbiome regulates much more than digestion.

It also influences:

Immune cell development
Inflammation
Cytokine production
T-cell activation
Production of beneficial metabolites such as short-chain fatty acids (SCFAs)

Researchers increasingly believe that these pathways may affect how myeloma develops—and how patients respond to treatment.

What Happens to the Microbiome During Induction Therapy?

Unfortunately, induction therapy often disrupts microbial diversity.

Common causes include:

Broad-spectrum antibiotics
Corticosteroids
Reduced appetite
Hospitalization
Dietary changes
Chemotherapy-related diarrhea

The result may be gut dysbiosis, meaning fewer beneficial bacteria and more potentially harmful organisms.

Several studies have linked reduced microbial diversity with:

Increased infections
More inflammation
Poorer immune recovery
Worse transplant outcomes

Although much of the strongest evidence comes from stem cell transplant studies, similar mechanisms likely begin during induction therapy.

The Gut–Bone Marrow Connection

One of the most fascinating discoveries is that bacteria in the intestine appear capable of influencing immune activity inside the bone marrow.

Researchers have identified several possible mechanisms.

1. Short-chain fatty acids (SCFAs)

Beneficial bacteria produce:

Butyrate
Acetate
Propionate

These compounds help:

Reduce inflammation
Strengthen the intestinal barrier
Improve regulatory immune responses
Support anti-cancer immunity

Higher levels of butyrate-producing bacteria may create a more favorable immune environment for myeloma treatment.

2. IL-17 and Th17 Cells

Animal studies suggest that certain gut bacteria stimulate Th17 cells, which migrate to the bone marrow and produce IL-17, a cytokine that may promote myeloma progression.

In mouse models, reducing these bacteria slowed disease progression.

Researchers caution that this has not yet been proven as a treatment strategy in humans.

3. Nitrogen-Recycling Bacteria

Some intestinal bacteria produce glutamine and other metabolites that may provide fuel for rapidly dividing myeloma cells.

Whether modifying these bacteria improves patient outcomes remains under investigation.

Can Diet Improve Induction Therapy?

No diet has been proven to increase remission rates during induction therapy.

However, diets that support microbial diversity are associated with healthier immune function.

These generally emphasize:

Vegetables
Fruit
Beans
Lentils
Whole grains
Nuts
Seeds
Fermented foods (if approved by your oncologist)
Olive oil

These foods provide dietary fiber that beneficial gut bacteria convert into SCFAs.

Foods That Feed Beneficial Bacteria

Examples include:

Oats
Barley
Garlic
Onions
Asparagus
Apples
Berries
Bananas
Chickpeas
Black beans
Lentils
Ground flaxseed

Foods That May Reduce Microbial Diversity

Frequent intake of:

Highly processed foods
Excess refined sugar
Artificial sweeteners (some evidence)
Excess alcohol
Ultra-processed snacks

may negatively affect microbial diversity in some individuals, although the evidence is still evolving.

Should You Take a Probiotic?

The answer is not automatically.

While probiotics are popular, patients undergoing induction therapy often become immunocompromised.

Rare cases of bloodstream infections from probiotic organisms have been reported in severely immunosuppressed patients.

Before taking probiotics:

Ask your hematologist
Ask your transplant physician (if a transplant is planned)
Consider food-based approaches first

Many experts currently favor increasing natural dietary fiber instead of routine probiotic supplementation.

Antibiotics: Sometimes Necessary—but Worth Using Carefully

Many myeloma patients receive antibiotics during induction therapy.

These drugs save lives.

However, broad-spectrum antibiotics can also reduce microbial diversity, particularly when used repeatedly or for prolonged periods.

This does not mean patients should avoid antibiotics when they are medically necessary. Instead, the goal is to use them appropriately while supporting recovery of the microbiome afterward through diet and careful medical management.

Could the Microbiome Affect New Myeloma Therapies?

Researchers are now studying whether gut bacteria influence responses to:

CAR-T therapy
Bispecific antibodies
Monoclonal antibodies
Stem cell transplantation

Early findings suggest that patients with healthier, more diverse microbiomes may experience stronger immune responses, but these observations remain preliminary and are not yet ready for routine clinical use.

Practical Ways to Support Your Gut During Induction Therapy

While no microbiome intervention has been proven to improve induction outcomes, many evidence-based habits support overall health:

Eat 25–35 grams of fiber daily if tolerated.
Include a variety of colorful plant foods.
Stay physically active as your energy allows.
Sleep adequately.
Avoid unnecessary antibiotic use while following your oncologist’s recommendations.
Stay well hydrated.
Discuss supplements with your oncology team before starting them.
Consider working with an oncology dietitian.

My Perspective as a Long-Term Survivor

One lesson I’ve learned over nearly three decades of surviving multiple myeloma is that successful cancer therapy isn’t just about fighting the disease—it’s about helping your body tolerate treatment and recover.

Evidence-based complementary therapies should never replace FDA-approved induction therapy. But they may help patients better tolerate treatment, reduce complications, and improve quality of life.

The gut microbiome is one of the most promising areas of integrative oncology research. Although we’re still waiting for large clinical trials, maintaining a healthy microbiome through nutrition and lifestyle is a low-risk strategy that supports overall health during one of the most challenging phases of myeloma treatment.

Frequently Asked Questions

Can changing my diet improve my induction therapy?

No study has shown that diet alone improves remission rates. However, a high-fiber, plant-rich diet supports gut bacteria that regulate immunity and inflammation.

Should every myeloma patient take probiotics?

No. Some patients, especially those with severe immunosuppression, should avoid probiotic supplements unless recommended by their oncology team.

Can antibiotics reduce treatment effectiveness?

Necessary antibiotics should never be avoided. However, repeated or prolonged broad-spectrum antibiotic use may reduce microbial diversity, which researchers are actively studying for its potential impact on treatment outcomes.

Does the microbiome matter after stem cell transplantation?

Yes. Strong evidence links greater microbial diversity after ASCT with improved immune recovery, fewer infections, and better outcomes, making microbiome preservation an active area of research.

Research Highlights

Gut dysbiosis is associated with inflammation, immune dysfunction, and multiple myeloma progression.
Butyrate-producing bacteria may support anti-inflammatory and anti-tumor immune responses.
Animal studies suggest gut bacteria influence Th17/IL-17 signaling involved in myeloma progression.
Reduced microbiome diversity after ASCT is associated with poorer immune recovery and higher infection risk.
Clinical trials are investigating whether the microbiome affects responses to immunotherapies such as CAR-T cells, bispecific antibodies, and monoclonal antibodies.

To learn more:

Improve Myeloma Induction Therapy Improve Myeloma Induction Therapy Improve Myeloma Induction Therapy

Our Mission